Conception, synthesis, and characterization of a rofecoxib-combretastatin hybrid drug with potent cyclooxygenase-2 (COX-2) inhibiting and microtubule disrupting activities in colon cancer cell culture and xenograft models

Tumor heterogeneity and drug resistance pose severe limitations to chemotherapy of colorectal cancers (CRCs) necessitating innovative approaches to trigger multiple cytocidal events for increased efficacy. Here, we developed a hybrid drug called KSS19 by combining the COX-2 selective NSAID rofecoxib...

Descripción completa

Detalles Bibliográficos
Autores principales: Punganuru, Surendra R., Madala, Hanumantha Rao, Mikelis, Constantinos M., Dixit, Anshuman, Arutla, Viswanath, Srivenugopal, Kalkunte S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995258/
https://www.ncbi.nlm.nih.gov/pubmed/29899846
http://dx.doi.org/10.18632/oncotarget.25450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995258/
https://www.ncbi.nlm.nih.gov/pubmed/29899846
http://dx.doi.org/10.18632/oncotarget.25450

Ejemplares similares